1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Autoimmune Drugs Market 2016-2020

Global Autoimmune Drugs Market 2016-2020

  • March 2016
  • -
  • Infiniti Research Limited
  • -
  • 137 pages

About Autoimmune Diseases Drugs

Autoimmune diseases are immunological disorders that occur when the immune system attacks and destroys healthy tissues in the body rather than foreign bodies, causing significant pain, inflammation, and organ damage. These diseases can affect the nervous system, cardiovascular system, and musculoskeletal system or individual organs, including the skin, lungs, kidneys, glands, and joints.
Autoimmune diseases occur due to genetic, infectious, or environmental factors. There are over 80 autoimmune diseases, including AS, IBD (CD and UC), MS, RA, SLE, and PsA. DMARDs, NSAIDs, corticosteroids, analgesics, and immunosuppressants are the major drug classes used to treat autoimmune diseases.

Technavio’s analysts forecast the global autoimmune diseases drugs market to grow at a CAGR of 5.57% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global autoimmune diseases drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of autoimmune diseases.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Autoimmune Diseases Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- AbbVie Inc.
- Amgen Inc.
- Biogen
- F. Hoffmann-La Roche
- Johnson & Johnson Private Limited
- Pfizer Inc.


Other prominent vendors
- Ablynx
- AB Science
- Acorda Therapeutics
- Alder BioPharmaceuticals
- Antares Pharma
- Astellas Pharma
- AstraZeneca
- Baxter
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Celltrion
- ChemoCentryx
- Coherus BioSciences
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Gilead Sciences
- GSK
- Hospira
- Idera Pharmaceuticals
- Immunomedics
- ImmuPharma
- Incyte
- Invion
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- Merck
- MedImmune
- Morphotek
- Novo Nordisk
- Novartis
- Opexa Therapeutics
- Principia Biopharma
- Regeneron Pharmaceuticals
- Sandoz
- Sanofi
- Santarus
- Takeda Pharmaceuticals
- UCB
- Vaccinex
- Vertex Pharmaceuticals
- Vitae Pharmaceuticals

Market driver
- Promising pipeline
- For a full, detailed list, view our report

Market challenge
- Loss of patent exclusivity of branded therapies
- For a full, detailed list, view our report

Market trend
- Increase in public awareness programs
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Autoimmune Drugs Market 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Assumptions
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Disease overview
- Understanding the disease
- Etiology
- Signs and symptoms
- Diagnosis
- Management
- Economic burden
- Epidemiology
PART 06: Pipeline portfolio
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by type of disease
- RA
- MS
- PsA
- IBD
- AS
- SLE
- Global RA drugs market
- Clinical trials for RA
- Global MS drugs market
- Global PsA drugs market
- Global IBD drugs market
- Global AS drugs market
- Global SLE drugs market
PART 09: Market segmentation by mechanism of action
- TNF inhibitors
- IL-1 blockers
- COX inhibitors
- PDE4 inhibitors
- Others
PART 10: Market segmentation by drug class
- DMARDs
- NSAIDs
- Corticosteroids
- Analgesics
- Immunosuppressants
- Others
PART 11: Market segmentation by type of molecule
- Biologics
- Small molecules
PART 12: Market segmentation by ROA
- Oral
- Parenteral
- Topical
PART 13: Market segmentation by dosage form
- Solid
- Liquid
- Semi-solid
PART 14: Geographical segmentation
- Autoimmune diseases drugs market in the Americas
- Autoimmune diseases drugs market in US
- Autoimmune diseases drugs market in EMEA
- Autoimmune diseases drugs market in APAC
- Autoimmune diseases drugs market in Japan
- Autoimmune diseases drugs market in China
PART 15: Market drivers
- Rising prevalence of autoimmune diseases
- Growing older population
- Dominance of biologics
- Unmet medical needs
- Promising pipeline
PART 16: Impact of drivers
PART 17: Market challenges
- Increasing cost of biologics
- Loss of patent exclusivity of branded therapies
- Complex nature of autoimmune diseases
- Preference for CAMs
- Adverse effects
PART 18: Impact of drivers and challenges
PART 19: Market trends
- Emergence of biosimilars
- Patient assistance programs
- Increase in public awareness programs
- Strategic alliances
- Popularity of off-label and traditional treatment options
PART 20: Vendor landscape
- Competitive scenario
- Market analysis 2015
- AbbVie
- Johnson and Johnson
- Biogen
- Amgen
- Pfizer
- F. Hoffmann-La Roche
- Other prominent vendors
PART 21: Appendix
- List of abbreviations
PART 22: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Etiology of autoimmune diseases
Exhibit 03: Signs and symptoms of autoimmune diseases
Exhibit 04: Diagnostic methods for autoimmune diseases
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases
Exhibit 07: Top drugs for autoimmune diseases
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions)
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions)
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions)
Exhibit 11: Prevalence and incidence of SLE
Exhibit 12: Pipeline molecules for RA
Exhibit 13: Pipeline molecules for MS
Exhibit 14: Pipeline molecules for PsA
Exhibit 15: Pipeline molecules for CD
Exhibit 16: Pipeline molecules for UC
Exhibit 17: Pipeline molecules for SLE
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020
Exhibit 23: Global RA drugs market 2015-2020 ($ billions)
Exhibit 24: Global RA drugs market by drug class 2015
Exhibit 25: Top-vendor offerings for global RA drugs market
Exhibit 26: RA clinical trial by Phase 2015
Exhibit 27: RA clinical trial by status 2015
Exhibit 28: Drivers and challenges of global RA drugs market
Exhibit 29: Global MS drugs market 2015-2020 ($ billions)
Exhibit 30: Global MS drugs market by molecule type 2015
Exhibit 31: Top-vendor offerings for global MS drugs market
Exhibit 32: Drivers and challenges of global MS drugs market
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions)
Exhibit 34: Global PsA drugs market segmentation by MOA 2015
Exhibit 35: Top-vendor offerings for global PsA drugs market
Exhibit 36: Drivers and challenges of global PsA drugs market
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions)
Exhibit 38: Global IBD drugs market by type of disease 2015
Exhibit 39: Global IBD drugs market by drug class 2015
Exhibit 40: Top-vendor offerings for global IBD drugs market
Exhibit 41: Drivers and challenges of global IBD drugs market
Exhibit 42: Global AS drugs market 2015-2020 ($ billions)
Exhibit 43: Global AS drugs market by MOA 2015
Exhibit 44: Top-vendor offerings for global AS drugs market
Exhibit 45: Drivers and challenges of global AS drugs market
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions)
Exhibit 47: Drivers and challenges of global SLE drugs market
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases
Exhibit 53: NSAIDs used to treat autoimmune diseases
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions)
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions)
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions)
Exhibit 66: Autoimmune diseases drugs market in America by country 2015
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions)
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions)
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions)
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions)
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 75: Population aged 60 years and over ($ millions)
Exhibit 76: Biologics approval timeline by US FDA
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases
Exhibit 78: Impact of drivers
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 80: Approval and patent expiries of top selling biologics
Exhibit 81: CAM therapies for autoimmune diseases
Exhibit 82: Usage of CAM therapies among individuals in US 2014
Exhibit 83: Adverse effects associated with autoimmune disease therapies
Exhibit 84: Impact of drivers and challenges
Exhibit 85: Patient assistance programs for autoimmune diseases drugs
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 88: AbbVie: Product segmentation by revenue 20150
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions)
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions)
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 92: Sales of HUMIRA in major markets
Exhibit 93: AbbVie: Key takeaways
Exhibit 94: Johnson and Johnson: Segmentation of key autoimmune diseases drugs 2014
Exhibit 95: Johnson and Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions)
Exhibit 96: Johnson and Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions)
Exhibit 97: Johnson and Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions)
Exhibit 98: Johnson and Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 99: Johnson and Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions)
Exhibit 100: Johnson and Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions)
Exhibit 101: Johnson and Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 102: Johnson and Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions)
Exhibit 103: Johnson and Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions)
Exhibit 104: Johnson and Johnson: Key takeaways
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015
Exhibit 106: Top selling autoimmune diseases drugs
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions)
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions)
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions)
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions)
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions)
Exhibit 112: Biogen: Key takeaways
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions)
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions)
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions)
Exhibit 116: Amgen: Key takeaways
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014
Exhibit 118: Top selling autoimmune diseases drugs
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions)
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions)
Exhibit 122: Pfizer: Key takeaways
Exhibit 123: Top selling autoimmune diseases drugs
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 129: F. Hoffmann-La Roche: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Scleroderma Diagnostics and Therapeutics Market: Overview Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and ...

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Ankylosing spondylitis (AS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Vitiligo - Market Insights, Epidemiology and Market Forecast-2023

Vitiligo - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Vitiligo - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


Download Unlimited Documents from Trusted Public Sources

Influenza Statistics in the US

  • February 2017
    9 pages
  • Influenza  

  • United States  

View report >

Autoimmune Disease Statistics in the US

  • February 2017
    9 pages
  • Autoimmune Dise...  

    Hospital  

  • United States  

View report >

Influenza Statistics in the US

  • February 2017
    9 pages
  • Influenza  

  • United States  

View report >

Chromosome Industry

13 days ago

Related Market Segments :

Autoimmune Disease
Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.